Olverembatinib (HQP1351) in Combination with Lisaftoclax Overcomes Venetoclax Resistance in Preclinical Model of Acute Myeloid Leukemia (AML)

被引：0
|
作者：
Xiong, Yan [1 ]
Liang, Zhiyan [2 ]
Min, Ping [1 ]
Wu, Bingxing [1 ]
Yu, Huidan [1 ]
Yang, Dajun [1 ,2 ,3 ]
Zhai, Yifan [1 ,2 ]
机构：
[1] Ascentage Pharm Suzhou Co Ltd, Suzhou, Peoples R China
[2] Ascentage Pharm Grp Inc, Rockville, MD USA
[3] Sun Yat sen Univ, Collaborat Innovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-202699
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5777 / 5778
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Olverembatinib (HQP1351) Combined with Lisaftoclax (APG-2575) in Children and Adolescents with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (R/R Ph plus ALL): First Report from a Phase 1 Study
    Zhang, Jingliao
    Wang, Junxia
    Guo, Huanshan
    Liu, Tianfeng
    Zhang, Xiaoyan
    Zhang, Ranran
    Ruan, Min
    Chang, Lixian
    Liu, Xiaoming
    Ren, Yuanyuan
    Chen, Xia
    Wang, Hengbang
    Chen, Zi
    Zhang, Yingchi
    Chen, Yumei
    Zhang, Li
    Guo, Ye
    Liu, Fang
    Chen, Xiaojuan
    Zou, Yao
    Yang, Wenyu
    Zhai, Yifan
    Zhu, Xiaofan
    BLOOD, 2024, 144 : 1443 - 1444
  • [22] Preclinical evaluation of sorafenib in combination with rapamycin for the treatment of acute myeloid leukemia (AML)
    Hu, Shuiying
    Niu, Hongmei
    Shimada, Akira
    Orwick, Shelley
    Inaba, Hiroto
    Rubnitz, Jeffrey
    Baker, Sharyn D.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3593S - 3593S
  • [23] Preclinical evaluation of sorafenib in combination with cytarabine and clofarabine in acute myeloid leukemia (AML)
    Hu, Shuiying
    Niu, Hongmei
    Orwick, Shelley
    Rubnitz, Jeffrey
    Schuetz, John
    Baker, Sharyn D.
    BLOOD, 2007, 110 (11) : 118B - 118B
  • [24] Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third -Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML)
    Qian, Jiang
    Shi, Dayu
    Li, Zongru
    Qin, Yazhen
    Zhao, Ting
    Liu, Bingcheng
    Chen, Zi
    Niu, Qian
    Men, Lichuang
    Wang, Hengbang
    Yang, Dajun
    Zhai, Yifan
    Huan, Xiaojun
    BLOOD, 2021, 138
  • [25] Olverembatinib (HQP1351) Overcomes Resistance/Intolerance to Asciminib and Ponatinib in Patients (pts) with Heavily Pretreated Chronic-Phase Chronic Myeloid Leukemia (CP-CML): A 1.5-Year Follow-up Update with Comprehensive Exposure-Response (E-R) Analyses
    Jabbour, Elias
    Jamy, Omer
    Koller, Paul B.
    Oehler, Vivian G.
    Baer, Maria R.
    Lomaia, Elza
    Hunter, Anthony M.
    Uspenskaya, Olga
    Samarina, Svetlana
    Cortes, Jorge E.
    Mukherjee, Sudipto
    Kim, Dennis Dong Hwan
    Zherebtsova, Vera
    Shuvaev, Vasily
    Turkina, Anna
    Davydkin, Igor
    Guo, Huanshan
    Chen, Zi
    Wang, Hengbang
    Fu, Tommy
    Jiang, Lixin
    Yang, Zhihong
    Wang, Cunlin
    Yang, Dajun
    Zhai, Yifan
    Kantarjian, Hagop
    BLOOD, 2024, 144 : 3151 - 3153
  • [26] Durable response with venetoclax in combination with decitabine or azacitadine in elderly patients with acute myeloid leukemia (AML).
    Dinardo, Courtney Denton
    Pratz, Keith William
    Potluri, Jalaja
    Pullarkat, Vinod A.
    Jonas, Brian Andrew
    Wei, Andrew H.
    Becker, Pamela Sue
    Frankfurt, Olga
    Xu, Tu
    Hong, Wan-Jen
    Chyla, Brenda
    Pollyea, Daniel Aaron
    Letai, Anthony G.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Durable Response with Venetoclax in Combination with Decitabine or Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)
    DiNardo, Courtney D.
    Pratz, Keith
    Potluri, Jalaja
    Pullarkat, Vinod
    Jonas, Brian A.
    Wei, Andrew H.
    Becker, Pamela S.
    Frankfurt, Olga
    Xu, Tu
    Hong, Wan-Jen
    Chyla, Brenda
    Pollyea, Daniel A.
    Letai, Anthony
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S201 - S201
  • [28] Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens
    Li, Zongru
    Ting, Zhao
    Hu, Lijuan
    Duan, Wenbing
    Jiang, Qian
    BLOOD, 2023, 142
  • [29] Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
    Jabbour, Elias J.
    Kantarjian, Hagop
    Issa, Ghayas C.
    Beck, Joseph Thaddeus
    Klisovic, Rebecca B.
    Mukherjee, Sudipto
    Oehler, Vivian G.
    Chen, Zi
    Lu, Ming
    Fu, Tommy
    Jiang, Lixin
    Zhai, Yifan
    Yang, Dajun
    BLOOD, 2021, 138
  • [30] Cephalochromin-Induced Mitochondrial Damage Overcomes Venetoclax-Resistance in Acute Myeloid Leukemia Models
    Do Nascimento, Mariane Cristina
    Pereira-Martins, Diego A.
    Alcantara, Guilherme Augusto Sousa
    Lima, Keli
    Vicari, Hugo Passos
    Pena Ferreira, Marcelo Jose
    Costa-Lotufo, Leticia Veras
    Huls, Gerwin A.
    Schuringa, Jan Jacob
    Machado-Neto, Joao Agostinho
    Rego, Eduardo Magalhaes
    BLOOD, 2023, 142
12345